News & Insights

This is where we share our own and our portfolio companies’ press releases as well as relevant Sunstone articles, analyses and SoMe posts.

5 latest press releases

Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...

Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies

Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joining...

Alligator Bioscience appoints Søren Bregenholt as new CEO

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søren Bregenholt, Ph.D. as the company’s new Chief Executive Officer (CEO), to strengthen Alligator’s business development activities and clinical progress on an...

Ascelia Pharma has carried out a directed new share issue raising SEK 200 million

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has successfully carried out a directed new share issue of 5,000,000 ordinary shares at a subscription price of SEK 40 per share, subject to the approval of an Extra General Meeting (the...

Zealand Pharma completes registration of capital increase

Zealand Pharma A/S announces that it has today, as part of completion of a directed issue and private placement (the "Offering"), registered with the Danish Business Authority, the capital increase of DKK 3,600,841, divided into 3,600,841 ordinary shares (the "New...

5 latest articles

Best country for sourcing new deals?

Do you also in your mind have a priority list of destinations to visit once the world normalises and you can get back on a plane? If so, and if you are a Venture Capitalist, you may also be wondering which countries have been creating most Life Science M&A...

Why are we investing in Drug Development and hesitating with regards to Medical Devices or Diagnostics?

Part of the answer is obviously that our past experiences and successes fall within Drug Development – but also that both MedTech and Diagnostics seem to have a lower likelihood of getting to an exit once you have invested. Defining the field for Medical Devices and...

Increasing the investor return multiple with an IPO?

For private company M&A the multiple stayed below 5x after a company had raised more than EUR 45M (https://bit.ly/36dPAVy). We have now added 12 European M&As completed after an IPO. The figure below shows the “Grand return multiple”, i.e. our calculation of...

To IPO… or not to IPO

We have recently added 12 venture funded companies to our M&A analysis of European therapeutic companies acquired post-IPO. As expected, those companies were acquired at a later developed stage. As previously highlighted most European venture capital funded...

Modest interest in Human Safety!?

We have previously highlighted that most European venture capital funded therapeutic companies are acquired after receiving less than EUR 45M in venture capital funding. It also appears that companies are acquired either before EUR 10M have been invested or after an...

The best VC’s for developing Therapeutics in Europe?

The VC’s investing in Europe can be ranked by the number of times they have participated in a EUR >50M M&A of a company developing therapeutics. In Sunstone’s analysis of the 56 M&As that took place in the period 2010-2020, 243 named investors participated....

News Archive

Articles Archive

Best country for sourcing new deals?

Do you also in your mind have a priority list of destinations to visit once the world normalises and you can get back on a plane? If so, and if you are a Venture Capitalist, you may also be wondering which countries have been creating most Life Science M&A...

To IPO… or not to IPO

We have recently added 12 venture funded companies to our M&A analysis of European therapeutic companies acquired post-IPO. As expected, those companies were acquired at a later developed stage. As previously highlighted most European venture capital funded...

Modest interest in Human Safety!?

We have previously highlighted that most European venture capital funded therapeutic companies are acquired after receiving less than EUR 45M in venture capital funding. It also appears that companies are acquired either before EUR 10M have been invested or after an...

Beating the odds

What do you think? Let us know in our feed on LinkedIn:  Using Pitchbook® we have identified 56, EUR >50M, M&A transactions of VC funded companies developing therapeutics from 2010 to 2020 and have modelled the investor cash flow in each of the companies....

Get news in your inbox

By signing up here, you will receive our Press Releases.Typically 4-6 / year.